Analyst: Priority review for Lundbeck-Otsuka Alzheimer's agitation drug signals unmet need
A four-month reduction to case processing is positive and could boost Lundbeck stock, says an analyst, noting that the regulatory win is also recognition of an unmet medical need.
by marketwire, translated by daniel pedersen
It doesn’t come as a huge surprise for Søren Løntoft Hansen, analyst at Danish bank Sydbank, that Lundbeck and its partner, Otsuka Pharmaceutical, have won priority review of their Alzheimer’s agitation treatment candidate brexpiprazol by the US Food and Drug Administration, FDA.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Extra data boosts Lundbeck's agitation case
For subscribers
.jpg&w=384&q=75)
